Tradestie Institutional Equity Comparison Engine

CGEN vs OABI โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CGEN Overall Edge

CGEN Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Compugen Ltd (CGEN) driven by superior Valuation, Growth & Margin while OABI counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, CGEN trades at 12.4x Forward P/E with 41.3% operating margin (+102.1% YoY revenue) versus OABI at N/M Forward P/E and -92.9% operating margin (+78.3% YoY). In options structure, CGEN sits in BREAKDOWN (57th %ile IV; Dealer Gamma Walls on Pro) against OABI sits in SURGE (20th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CGEN
CGEN 12.4x vs OABI N/M Fwd P/E
Growth & Margin Winner CGEN
Op Margin 41.3% vs -92.9% ยท YoY +102.1% vs +78.3%
Momentum & Technical Winner OABI
1Y +23.2% vs +223.7% ยท 52W Pos 33% vs 90%
Options & Structure Winner OABI
BREAKDOWN (57th %ile IV) vs SURGE (20th %ile IV)
CGEN NASDAQ
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap $193.2M
1M Return +2.54%
1Y Return +23.17%
Forward P/E 12.4x
Unified AI Score
47.1 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 54.0 Mom 64.0
OABI NASDAQ
OmniAb, Inc. Common Stock
Services-Commercial Physical & Biological Research
$5.05
+3.27% 1D
Market Cap $713.3M
1M Return +7.68%
1Y Return +223.72%
Forward P/E N/M
Unified AI Score
56.2 / 100 HOLD
Tech 50.0 Fund 51.0 Flow 54.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CGEN +23.17% OABI +223.72% Spread: +200.55 pp (OABI Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CGEN Revenue OABI Revenue CGEN Op. Margin OABI Op. Margin Margin Edge
FY2016 $0M N/A -4576.3% N/A CGEN
FY2018 $20M N/A -130.5% N/A CGEN
FY2020 $0M N/A -1574.8% N/A CGEN
FY2021 $10M $30M -584.6% -102.5% OABI
FY2022 $10M $60M -471.7% -45.1% OABI
FY2023 $30M $30M -38.8% -203.2% CGEN
FY2024 $30M $30M -53.4% -282.3% CGEN
FY2025 $70M $20M 43.1% -369.5% CGEN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CGEN (6) vs OABI (4)
Institutional Metric CGEN OABI Criterion Row Winner
Market Capitalization Scale $193.2M $713.3M Larger Scale OABI
Trailing P/E Ratio Valuation 5.2x N/M Lower Multiple CGEN
Forward P/E Ratio Valuation 12.4x N/M Lower Multiple CGEN
Revenue Growth (YoY) Growth +102.1% +78.3% Higher Growth CGEN
Operating Margin (TTM) Profitability 41.3% -92.9% Higher Margin CGEN
Net Profit Margin Profitability 47.9% -108.1% Higher Margin CGEN
Return on Equity (ROE) Capital Efficiency 57.2% -16.5% Higher ROE CGEN
52-Week Range Position Momentum 33% ($1โ€“$3) 90% ($1โ€“$5) Stronger Trend OABI
Beta / 30D Volatility Risk Regime 1.44ฮฒ ยท 62% Vol 1.23ฮฒ ยท 57% Vol Lower Realized Risk OABI
Unified Institutional Score Composite Signal 47.1 / 100 (HOLD) 56.2 / 100 (HOLD) Higher Composite OABI

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CGEN vs OABI Buy Guide
CGEN BREAKDOWN
143d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 57th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CGEN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
OABI SURGE
14d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 20th %ile
IV Regime Compressed (<25th %ile)
Live OABI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CGEN nor OABI registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.